ArticleAnnals of surgical oncology2025
Peritoneal Lavage Cytology Predicts Peritoneal Metastasis and is Associated with Poor Prognosis in Patients with Stage II-III Colorectal Cancer.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07478107 (Application of the One-step Nucleic Acid Amplification), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Application of the One-step Nucleic Acid Amplification (OSNA) Assay to Detect Free Cancer Cells in the Peritoneal Washing of Gastric and Colon Cancer Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPeritoneal lavage cytology (PLC) is used to detect peritoneal micrometastases in gastrointestinal malignancies, but its prognostic value in colorectal cancer (CRC) remains controversial, particularly in stage II-III. We aimed to evaluate the prognostic significance of PLC in predicting postoperative outcomes and peritoneal metastasis risk among patients with stage II-III CRC, thereby facilitating individualized treatment strategies. PATIENTS AND
methodsA retrospective analysis was performed on 375 patients with stage II-III CRC who underwent curative resection with standardized intraoperative PLC between January 2017 and August 2018. Survival outcomes, including 5-year disease-free survival (DFS), overall survival (OS), and cancer-specific survival (CSS), were assessed using Kaplan-Meier analysis and Cox regression models. A prognostic nomogram incorporating PLC status along with other clinicopathological factors was developed and validated using area under the curve (AUC), C-index, and calibration curves. A competing risk analysis was performed to further elucidate the association between PLC positivity and specific metastasis patterns.
resultsPLC positivity, observed in 9.9% of patients, predicted reduced 5-year DFS and CSS, particularly in stage II patients, but not in stage III patients. Multivariate analysis identified PLC positivity as an independent prognostic factor for DFS (HR = 2.35, 95% CI 1.11-4.95, P = 0.025), along with preoperative CA199, tumor location, lymphovascular invasion, and N stage. The prognostic model demonstrated excellent discrimination (C-index = 0.796) and calibration. In addition, PLC-positive patients exhibited a significantly higher risk of peritoneal metastasis.
conclusionsPLC is a valuable prognostic tool for the early detection of micrometastatic risk and peritoneal dissemination in stage II-III CRC, particularly in stage II disease.
Indexed as
Identifiers
40887569What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.